Advances and challenges in therapeutic targeting of NRF2

Albena T. Dinkova-Kostova (Lead / Corresponding author), Ian M. Copple (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

Abstract

Activation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is emerging as an attractive therapeutic approach to counteract oxidative stress, inflammation, and metabolic imbalances. These processes underpin many chronic pathologies with unmet therapeutic needs, including neurodegenerative disorders and metabolic diseases. As the NRF2 field transitions into the clinical phase of its evolution, the need for an understanding of the factors influencing NRF2 pharmacology has never been greater. In this opinion article we describe the rationale for targeting NRF2, summarise the recent advances in drug development of NRF2 modulators, and reflect on the remaining challenges in realising the full clinical potential of NRF2 as a therapeutic target.

Original languageEnglish
Number of pages13
JournalTrends in Pharmacological Sciences
DOIs
Publication statusE-pub ahead of print - 9 Jan 2023

Keywords

  • NRF2
  • KEAP1
  • electrophile
  • oxidative stress
  • inflammation
  • chronic disease

Fingerprint

Dive into the research topics of 'Advances and challenges in therapeutic targeting of NRF2'. Together they form a unique fingerprint.

Cite this